TrialMolecular cancer2023

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

Linlin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.